Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten ...

Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn).

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.

Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for Hypercon technology.

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled ...

Rare kidney trials miss enrollment timelines for the same reason most clinical projects fail: eligible patients reach sites too slowly and in insufficient numbers.

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

As healthcare accelerates toward data intensive innovation, mounting pressure on hospital networks is exposing an uncomfortable truth: many are not ready.

In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.